← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

NAD+ × 5-Amino-1MQ × 2 of 4 selected View comparison

NAD+

Cellular redox cofactor

Remove
VS

5-Amino-1MQ

NNMT inhibitor

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target NAD+5-Amino-1MQ
✓ —
— ✓

What These Compounds Share

Shared research line

All selected compounds are catalogued under Metabolic.

Key Differences

NAD+ NAD+ is a direct target of NAD+ that none of the other selected compounds share. A cellular cofactor rather than a receptor-targeting peptide -- the only non-peptide, non-small-molecule compound in this catalogue.
5-Amino-1MQ NNMT is a direct target of 5-Amino-1MQ that none of the other selected compounds share. The only small-molecule enzyme inhibitor in the current catalogue.

Compound Detail

NAD+
What is it?
A natural molecule every cell needs to make energy and repair itself.
What are people researching/using it for?
Studied for cellular energy, ageing biology and general vitality research.
Other uses being trialed
DNA repair supportMitochondrial health
Worth knowing
Direct administered-NAD+ human research is considerably more limited than research on precursors (NR/NMN) -- those findings are not transferred to NAD+ itself here. A small human pilot study (8 IV-NAD+ participants, 3 controls) has directly measured plasma/urinary NAD+ metabolite changes during a 6-hour infusion -- real human PK-adjacent data, but from a small sample and without an efficacy endpoint.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A cellular redox cofactor central to electron transfer, NAD+/NADH reactions, and as a substrate for sirtuins and PARP enzymes.
Dinucleotide / coenzyme -- not a peptide · Endogenous
Primary Targets & Biological System
Cellular energy / redox metabolism

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
NAD+ is not a signalling molecule that binds a receptor -- it is a coenzyme every cell uses directly in metabolism, shuttling electrons in the reactions that generate cellular energy (the NAD+/NADH redox couple). It also serves as a required substrate for two enzyme classes: sirtuins, involved in various regulatory cellular processes, and PARP enzymes, involved in DNA repair. Because it is consumed as a substrate rather than acting as a switch, its effects are tied to overall cellular NAD+ availability rather than a conventional single-target dose-response.
Research Areas
Cellular energeticsMitochondrial biologyRedox metabolismDNA repair biologyAge-associated NAD metabolism
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
No universal half-life value is displayed for this cofactor.
Research Routes
Intravenous (research contexts) (descriptive only — not administration or dosing guidance)
Key Differentiator
A cellular cofactor rather than a receptor-targeting peptide -- the only non-peptide, non-small-molecule compound in this catalogue.
Considerations
Research Limitations
Direct administered-NAD+ human research is considerably more limited than research on precursors (NR/NMN) -- those findings are not transferred to NAD+ itself here. A small human pilot study (8 IV-NAD+ participants, 3 controls) has directly measured plasma/urinary NAD+ metabolite changes during a 6-hour infusion -- real human PK-adjacent data, but from a small sample and without an efficacy endpoint.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Addiction / withdrawal support
IV NAD+ is widely marketed at private clinics for opioid and alcohol withdrawal, with some small studies reporting reduced craving/withdrawal scores. Addiction researchers have specifically cautioned that this evidence is weak -- much of it traces back to research from the 1960s with roughly 100 participants -- and that withdrawal-symptom relief is not the same as addiction recovery. Treat this as a heavily-marketed but thinly-evidenced use, not an established one.
Infusion tolerability (real-world clinic data)
A retrospective review of a commercial IV-therapy clinic's own records (four consecutive days of 500 mg IV NAD+) reported moderate-to-severe infusion-related symptoms (GI upset, increased heart rate, chest pressure) that resolved by the end of each infusion, plus some lab-value changes. This is real-world tolerability data, not a controlled efficacy trial -- and the authors are employees of the commercial IV-wellness company whose clients were reviewed, a disclosed conflict of interest worth weighing.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
NAD+ · A$159.95 A$179.95
Browse products →
View Research Sources (2) →
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+
Frontiers in Aging Neuroscience, 2019 · Human Human · 11 male participants (8 NAD+, 3 saline control), aged 30-55 · Intravenous · PMID 31572171 · DOI 10.3389/fnagi.2019.00257

Measured plasma and urinary NAD+, nicotinamide, ADPR, methylnicotinamide and NMN at multiple timepoints. Real human PK-adjacent data on administered NAD+ itself, but a small pilot with no efficacy endpoint.

Supports: mechanism_summary, research_limitations

Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting
Frontiers in Aging, 2026 · Human Human · Retrospective EMR review of commercial IV-therapy clinic clients · Intravenous · PMID 41704678 · DOI 10.3389/fragi.2026.1652582

Reported moderate-to-severe infusion-related GI symptoms, increased heart rate and chest pressure during infusions (resolved by end of infusion), longer infusion times than nicotinamide riboside, and some lab-value changes (ALP decrease, HDL-C reduction). Real-world tolerability data, not a controlled efficacy trial. Authors are employees of the commercial IV-wellness company whose clients were reviewed -- a disclosed conflict of interest.

Supports: experimental_research

5-Amino-1MQ
What is it?
A small lab-made molecule (not a peptide) that blocks a specific metabolism-related enzyme.
What are people researching/using it for?
Studied in animal models for fat metabolism and body composition.
Other uses being trialed
General metabolic research -- still early-stage, no human studies yet
Worth knowing
No established human administration research identified -- current evidence is preclinical.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
An NNMT inhibitor investigated in relation to nicotinamide metabolism, methyl-donor metabolism and NAD-linked metabolic pathways.
Small molecule -- not a peptide · Synthetic small molecule
Primary Targets & Biological System
Nicotinamide / NAD-linked metabolism

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A small molecule that inhibits NNMT, an enzyme that transfers a methyl group onto nicotinamide (a B3-vitamin-related compound) as part of its breakdown. Because this reaction consumes methyl donors and intersects with NAD+ metabolism, inhibiting NNMT has been investigated in mouse models for effects on adipose tissue metabolism and body weight. This mechanistic link between NNMT activity, methyl-donor availability and metabolic outcomes has substantial preclinical support but has not yet been evaluated in human trials.
Research Areas
NNMT biologyMetabolismAdipose biologyNAD-related metabolismSkeletal-muscle/metabolic research
Research Profile
Human administration: None identified Preclinical: Available
Pharmacokinetics
Not established
Research Routes
Not established in humans (descriptive only — not administration or dosing guidance)
Key Differentiator
The only small-molecule enzyme inhibitor in the current catalogue.
Considerations
Research Limitations
No established human administration research identified -- current evidence is preclinical.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
5-Amino-1MQ · A$149.95 A$169.95
Browse products →
View Research Sources (1) →
Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction
Preclinical (animal) Mouse · PMID 39161060

Mouse work -- its PK/metabolic findings are not presented as human PK on this record.

Supports: mechanism_summary, human_administration_status

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.